stockrow
Saturday 7 November 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
3.92
0.16
+4.26%
Follow MNKD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
255.41 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.97 | 2.09 | 3.35 | 3.02 | |
P/FCF ratio |
126.60 | 57.43 | 0.00 | 0.00 | |
P/Operating CF |
(217.76) | (140.77) | (71.70) | (36.14) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.79 | 2.89 | 4.14 | 3.81 | |
EV/EBITDA |
38.89 | 32.02 | 51.74 | 50.03 | |
EV/Operating CF |
110.64 | 54.15 | (202.15) | (23.76) | |
EV/FCF |
147.54 | 79.33 | (89.78) | (20.08) | |
Quick Ratio |
1.23 | 1.20 | 1.08 | 1.27 | |
Current Ratio |
1.70 | 1.87 | 1.72 | 2.22 | |
Net Debt/EBITDA |
(95.76) | 50.54 | 45.02 | 0.00 | |
Debt/Assets |
57.82% | 56.68% | 57.64% | 0.00% | |
Debt/Equity |
(8.98) | (7.13) | (6.28) | 0.00 | |
Asset Turnover |
0.59 | 0.63 | 0.69 | 0.68 | |
Operating CF/Net income |
0.50 | 0.32 | 0.97 | 1.49 | |
Capex/Depreciation |
(0.42) | (0.26) | (0.70) | 0.00 | |
Interest Coverage |
(0.55) | (0.13) | (0.02) | — | |
Research and Development Expense of Revenue |
24.64% | 19.11% | 16.46% | 14.10% | |
Selling, General and Administrative Expense of Revenue |
52.17% | 59.98% | 53.31% | 60.28% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
14.67% | 7.16% | 9.35% | 0.00% | |
Graham Net Nets |
(0.32) | (0.73) | (0.42) | (0.42) | |
Graham Number |
0.00 | 0.54 | 0.80 | 0.78 | |
Earnings Yield |
0.39% | (2.77%) | (3.05%) | (5.90%) | |
Free Cash Flow Yield |
0.79% | 1.74% | (1.38%) | (6.28%) | |
Revenue per Share |
0.37 | 0.29 | 0.35 | 0.32 | |
Operating CF per Share |
(0.03) | (0.02) | (0.06) | (0.11) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.03) | (0.02) | (0.08) | (0.12) | |
Cash per Share |
0.56 | 0.43 | 0.36 | 0.30 | |
Shareholders Equity per Share |
(0.17) | (0.19) | (0.22) | (0.12) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.17) | (0.19) | (0.22) | (0.12) | |
Free Cash Flow |
(9.95) | (7.24) | (23.45) | (37.76) | |
Working Capital |
120.55 | 116.60 | 102.81 | 131.95 | |
Capital Expenditures |
(1.99) | (1.88) | (5.08) | (3.21) | |
Net Current Asset Value |
(551.62) | (552.44) | (553.79) | (519.41) | |
EV/EBIT |
52.05 | 70.30 | 177.12 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.05 | 0.03 | |
Price to Operating Income |
44.66 | 50.89 | 143.29 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.09 | 28.52 | 35.17 | 29.21 | |
Average Payables |
7.91 | 10.59 | 10.65 | 10.83 | |
Average Inventory |
31.60 | 39.03 | 36.46 | 37.72 | |
Average Assets |
593.01 | 577.27 | 572.00 | 608.63 | |
Average Common Equity |
(64.92) | (58.91) | (61.12) | (40.91) |
Columns are period end dates · fundamentals updated 5 Nov 2026